Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders

Molecular Biology Reports

Volumn 39, Issue 2, 2012, Pages 2003-2010

  Noori Daloii, Mohammad Reza ^a   Mojarrad, Majid ^a   Rashidi Nezhad, Ali ^a   Kheirollahi, Majid ^a   Shahbazi, Ali ^a,b   Khaksari, Mehdi ^a   Korzebor, Asghar ^a   Goodarzi, Ali ^b   Ebrahimi, Maryam ^a   Noori Daloii, Ali Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b INSTITUTE FOR COGNITIVE SCIENCE STUDIES ICSS   (Iran)

Author keywords

D2DR; Dopamine receptors; Locomotion; Nucleus accumbens; Schizophrenia; SiRNA

Indexed keywords

APOMORPHINE; DOPAMINE RECEPTOR; MESSENGER RNA; PLASMID DNA; SMALL INTERFERING RNA; DOPAMINE RECEPTOR BLOCKING AGENT; OLIGONUCLEOTIDE; PRIMER DNA;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; HYPERACTIVITY; IN VITRO STUDY; LOCOMOTION; MALE; MENTAL DISEASE; NEUROBLASTOMA CELL; NEUROPSYCHIATRIC DISORDER; NONHUMAN; NUCLEUS ACCUMBENS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; ANALYSIS OF VARIANCE; ANIMAL; DRUG EFFECT; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; PLASMID; TUMOR CELL LINE;

RATTUS;

ANALYSIS OF VARIANCE; ANIMALS; CELL LINE, TUMOR; DNA PRIMERS; DOPAMINE ANTAGONISTS; GENE SILENCING; GENE THERAPY; LOCOMOTION; MENTAL DISORDERS; NUCLEUS ACCUMBENS; OLIGONUCLEOTIDES; PLASMIDS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 84860346739     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-0947-3     Document Type: Article

References (33)

1. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF (2007) Inverted-U dopamine D1 receptor actions on pre-frontal neurons engaged in working memory. Nat Neurosci 10:376-384
2. Floresco SB, Tse MT, Ghods-Sharifi S (2008) Dopaminergic and glutamatergic regulation of effort- and delay-based decision making. Neuropsychopharmacology 33:1966-1979 (Pubitemid 351832587)
3. Nieoullon A (2002) Dopamine and the regulation of cognition and attention. Prog Neurobiol 67:53-83 (Pubitemid 34786170)
4. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neuro-chemical correlations. J Neurol Sci 20:415-455
5. Grace AA, Floresco SB, Goto Y, Lodge DJ (2007) Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 30:220-227 (Pubitemid 46654234)
6. Rosenkranz JA, Grace AA (1999) Modulation of basolateral amygdala neuronal firing and afferent drive by dopamine receptor activation in vivo. J Neurosci 19:11027-11039 (Pubitemid 30235746)
7. Arnsten AF (2009) Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 23(Suppl 1):33-41
8. Bonci A, Bernardi G, Grillner P, Mercuri NB (2003) The dopa-mine-containing neuron: maestro or simple musician in the orchestra of addiction? Trends Pharmacol Sci 24:172-177 (Pubitemid 36428818)
9. Greene JG (2006) Gene expression profiles of brain dopamine neurons and relevance to neuropsychiatric disease. J Physiol 575:411-416 (Pubitemid 44270172)
10. Kebabian JW, Petzold GL, Greengard P (1972) Dopamine-sen-sitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor". Proc Natl Acad Sci USA 69:2145-2149
11. Seeman P, Chau-Wong M, Tedesco J, Wong K (1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci USA 72:4376-4380
12. Werkman TR, Glennon JC, Wadman WJ, McCreary AC (2006) Dopamine receptor pharmacology: interactions with serotonin receptors and significance for the aetiology and treatment of schizophrenia. CNS Neurol Disord Drug Targets 5:3-23 (Pubitemid 43796625)
13. Strange PG (1993) Dopamine receptors: structure and function. Prog Brain Res 99:167-179 (Pubitemid 24015893)
14. Vallone D, Picetti R, Borrelli E (2000) Structure and function of dopamine receptors. Neurosci Biobehav Rev 24:125-132 (Pubitemid 30026154)
15. Birkmayer W, Hornykiewicz O (1961) The L-3, 4-dioxyphenyl-alanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Woc-henschr 73:787-788
16. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normeta-nephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20: 140-144
17. Iversen SD, Iversen LL (2007) Dopamine: 50 years in perspective. Trends Neurosci 30:188-193 (Pubitemid 46654233)
18. Sah DW (2006) Therapeutic potential of RNA interference for neurological disorders. Life Sci 79:1773-1780 (Pubitemid 44441450)
19. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223 (Pubitemid 41345943)
20. Remington G, Kapur S (2010) Antipsychotic dosing: how much but also how often? Schizophr Bull 36:900-903
21. Schultz SH, North SW, Shields CG (2007) Schizophrenia: a review. Am Fam Physician 75:1821-1829 (Pubitemid 46954070)
22. Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59:75-86 (Pubitemid 46770900)
23. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811 (Pubitemid 28099681)
24. Kim DH, Rossi JJ (2007) Strategies for silencing human disease using RNA interference. Nat Rev Genet 8:173-184
25. Takahashi Y, Nishikawa M, Takakura Y (2009) Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. Adv Drug Deliv Rev 61:760-766
26. Thakker DR, Hoyer D, Cryan JF (2006) Interfering with the brain: use of RNA interference for understanding the patho-physiology of psychiatric and neurological disorders. Pharmacol Ther 109:413-438 (Pubitemid 43132820)
27. Makimura H, Mizuno TM, Mastaitis JW, Agami R, Mobbs CV (2002) Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci 3:18
28. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic Press, New York
29. Wadhwa R, Kaul SC, Miyagishi M, Taira K (2004) Know-how of RNA interference and its applications in research and therapy. Mutat Res 567:71-84 (Pubitemid 39162994)
30. Backman C, Zhang Y, Hoffer BJ, Tomac AC (2003) Short interfering RNAs (siRNAs) for reducing dopaminergic pheno-typic markers. J Neurosci Methods 131:51-56 (Pubitemid 37491459)
31. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R et al (2000) Increased baseline occupancy of D2 receptors by dopa-mine in schizophrenia. Proc Natl Acad Sci USA 97:8104-8109 (Pubitemid 30460780)
32. Barr AM, Powell SB, Markou A, Geyer MA (2006) Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 51:457-465 (Pubitemid 44215953)
33. Breysse N, Risterucci C, Amalric M (2002) D1 and D2 dopamine receptors contribute to the locomotor response induced by Group II mGluRs activation in the rat nucleus accumbens. Pharmacol Biochem Behav 73:347-357 (Pubitemid 34765574)